Experts in bioethics, law and policy from top universities in the US call for creative and collaborative policies to regulate the use and oversight of psychedelics for treating conditions like depression and post-traumatic stress disorder. In a paper published in the journal Science, the authors propose solutions to regulatory challenges in anticipation of FDA approval of psychedelics for medical use, while stressing the need for a strong evidence base for efficacy and safety.
